On Tuesday, Bharat Biotech International Ltd. announced the release of Hillchol, an innovative oral cholera vaccine with a single strain.
According to a statement released from the vaccine manufacturer, Bharat Biotech developed Hillchol (BBV131) to fight cholera under license from Hilleman Laboratories, which was funded by Merck USA and the Wellcome Trust.
The annual demand for oral cholera vaccines (OCVs) worldwide surpasses 100 million doses, indicating their critical role in cholera control. OCVs are in low supply worldwide because there is only one manufacturer. It added that BBIL had set up expansive manufacturing plants with the ability to create up to 200 million doses of Hillchol in Hyderabad and Bhubaneswar.
A multi-phase clinical development process that resulted in a Phase 3 study confirmed the safety, immunogenicity, and non-inferiority of the vaccine compared to current OCVs, indicating its potential for use in public health and white spirit.
For individuals older than one year, the vaccine, which consists of a single dose respule, can be given orally on days 0 and 14.
Join our whatsapp group for Latest updates